Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer

Masafumi Nakamura, Tadashi Kayashima, Kenji Fujiwara, Yosuke Nagayoshi, Hiroshi Kono, Takao Ohtsuka, Shunichi Takahata, Kazuhiro Mizumoto, Masao Tanaka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: Although adjuvant chemotherapy (AC) using gemcitabine improves the prognosis of patients with resectable pancreatic cancer, the effect of gemcitabine AC on the prognosis of patients with borderline resectable pancreatic cancer is not clear. Methodology: We analyzed the prognosis of patients with pancreatic cancer who underwent curative pancreatoduodenectomy or total pancreatectomy in combination with portal/superior mesenteric vein resection (PVR) [PVR (+) group] or without PVR [PVR(-) group]. Results: MST of the PVR (+) group was significantly shorter than that of the PVR(-) group (p=0.017). In contrast, when we focused on the patients with gemcitabine AC, there was no significant difference in MST between the PVR (+) and the PVR (-) groups (p=0.247]. Furthermore, we compared MST of two subgroups in the PVR (+) group depending on gemcitabine AC status. In the PVR (+) group, MST of the patients with gemcitabine AC was significantly longer than that without gemcitabine AC (p=0.003). This was also true for the patients with pancreatic cancer which had histologically proven invasion to portal/superior mesenteric vein (PV/SMV) (p=0.001). Conclusions: The prognosis of patients with pancreatic cancer invading PV/SMV can be improved by combination therapy with PVR and gemcitabine adjuvant chemotherapy.

Original languageEnglish
Pages (from-to)354-357
Number of pages4
JournalHepato-gastroenterology
Volume60
Issue number121
DOIs
Publication statusPublished - Jan 1 2013

Fingerprint

gemcitabine
Mesenteric Veins
Portal Vein
Pancreatic Neoplasms
Adjuvant Chemotherapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer. / Nakamura, Masafumi; Kayashima, Tadashi; Fujiwara, Kenji; Nagayoshi, Yosuke; Kono, Hiroshi; Ohtsuka, Takao; Takahata, Shunichi; Mizumoto, Kazuhiro; Tanaka, Masao.

In: Hepato-gastroenterology, Vol. 60, No. 121, 01.01.2013, p. 354-357.

Research output: Contribution to journalArticle

Nakamura, Masafumi ; Kayashima, Tadashi ; Fujiwara, Kenji ; Nagayoshi, Yosuke ; Kono, Hiroshi ; Ohtsuka, Takao ; Takahata, Shunichi ; Mizumoto, Kazuhiro ; Tanaka, Masao. / Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer. In: Hepato-gastroenterology. 2013 ; Vol. 60, No. 121. pp. 354-357.
@article{085a529d71c74a5ba637f96e5a626e82,
title = "Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer",
abstract = "Background/Aims: Although adjuvant chemotherapy (AC) using gemcitabine improves the prognosis of patients with resectable pancreatic cancer, the effect of gemcitabine AC on the prognosis of patients with borderline resectable pancreatic cancer is not clear. Methodology: We analyzed the prognosis of patients with pancreatic cancer who underwent curative pancreatoduodenectomy or total pancreatectomy in combination with portal/superior mesenteric vein resection (PVR) [PVR (+) group] or without PVR [PVR(-) group]. Results: MST of the PVR (+) group was significantly shorter than that of the PVR(-) group (p=0.017). In contrast, when we focused on the patients with gemcitabine AC, there was no significant difference in MST between the PVR (+) and the PVR (-) groups (p=0.247]. Furthermore, we compared MST of two subgroups in the PVR (+) group depending on gemcitabine AC status. In the PVR (+) group, MST of the patients with gemcitabine AC was significantly longer than that without gemcitabine AC (p=0.003). This was also true for the patients with pancreatic cancer which had histologically proven invasion to portal/superior mesenteric vein (PV/SMV) (p=0.001). Conclusions: The prognosis of patients with pancreatic cancer invading PV/SMV can be improved by combination therapy with PVR and gemcitabine adjuvant chemotherapy.",
author = "Masafumi Nakamura and Tadashi Kayashima and Kenji Fujiwara and Yosuke Nagayoshi and Hiroshi Kono and Takao Ohtsuka and Shunichi Takahata and Kazuhiro Mizumoto and Masao Tanaka",
year = "2013",
month = "1",
day = "1",
doi = "10.5754/hge12614",
language = "English",
volume = "60",
pages = "354--357",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "121",

}

TY - JOUR

T1 - Combination therapy of portal vein resection and adjuvant gemcitabine improved prognosis of advanced pancreatic cancer

AU - Nakamura, Masafumi

AU - Kayashima, Tadashi

AU - Fujiwara, Kenji

AU - Nagayoshi, Yosuke

AU - Kono, Hiroshi

AU - Ohtsuka, Takao

AU - Takahata, Shunichi

AU - Mizumoto, Kazuhiro

AU - Tanaka, Masao

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background/Aims: Although adjuvant chemotherapy (AC) using gemcitabine improves the prognosis of patients with resectable pancreatic cancer, the effect of gemcitabine AC on the prognosis of patients with borderline resectable pancreatic cancer is not clear. Methodology: We analyzed the prognosis of patients with pancreatic cancer who underwent curative pancreatoduodenectomy or total pancreatectomy in combination with portal/superior mesenteric vein resection (PVR) [PVR (+) group] or without PVR [PVR(-) group]. Results: MST of the PVR (+) group was significantly shorter than that of the PVR(-) group (p=0.017). In contrast, when we focused on the patients with gemcitabine AC, there was no significant difference in MST between the PVR (+) and the PVR (-) groups (p=0.247]. Furthermore, we compared MST of two subgroups in the PVR (+) group depending on gemcitabine AC status. In the PVR (+) group, MST of the patients with gemcitabine AC was significantly longer than that without gemcitabine AC (p=0.003). This was also true for the patients with pancreatic cancer which had histologically proven invasion to portal/superior mesenteric vein (PV/SMV) (p=0.001). Conclusions: The prognosis of patients with pancreatic cancer invading PV/SMV can be improved by combination therapy with PVR and gemcitabine adjuvant chemotherapy.

AB - Background/Aims: Although adjuvant chemotherapy (AC) using gemcitabine improves the prognosis of patients with resectable pancreatic cancer, the effect of gemcitabine AC on the prognosis of patients with borderline resectable pancreatic cancer is not clear. Methodology: We analyzed the prognosis of patients with pancreatic cancer who underwent curative pancreatoduodenectomy or total pancreatectomy in combination with portal/superior mesenteric vein resection (PVR) [PVR (+) group] or without PVR [PVR(-) group]. Results: MST of the PVR (+) group was significantly shorter than that of the PVR(-) group (p=0.017). In contrast, when we focused on the patients with gemcitabine AC, there was no significant difference in MST between the PVR (+) and the PVR (-) groups (p=0.247]. Furthermore, we compared MST of two subgroups in the PVR (+) group depending on gemcitabine AC status. In the PVR (+) group, MST of the patients with gemcitabine AC was significantly longer than that without gemcitabine AC (p=0.003). This was also true for the patients with pancreatic cancer which had histologically proven invasion to portal/superior mesenteric vein (PV/SMV) (p=0.001). Conclusions: The prognosis of patients with pancreatic cancer invading PV/SMV can be improved by combination therapy with PVR and gemcitabine adjuvant chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84877702464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877702464&partnerID=8YFLogxK

U2 - 10.5754/hge12614

DO - 10.5754/hge12614

M3 - Article

C2 - 23574657

AN - SCOPUS:84877702464

VL - 60

SP - 354

EP - 357

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 121

ER -